VISCHER advises Resistell with series B first tranche of CHF 8.5m

Resistell, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF 8.5million from new and existing investors. Investors include EIC Fund, TRUMPF Venture, OCCIDENT, Zürcher Kantonalbank, Launchpad, and private investors. The funds will be used to complete the company’s clinical trials for antibiotic susceptibility testing (AST) and for market entry of its R&D device Phenotech Research.

VISCHER acted as legal advisor to Resistell in the series B financing round. The team includes Christian Wyss (partner, corporate / m&a, pictured), Timothy Woodtli (associate, corporate / m&a), Michael Maurer (associate, corporate / m&a), Bettina Fischer (junior associate, corporate / m&a), Adrian Briner (managing associate, tax) and Jannick Walleser (associate, tax).